<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05025410</url>
  </required_header>
  <id_info>
    <org_study_id>B-2109-706-301</org_study_id>
    <nct_id>NCT05025410</nct_id>
  </id_info>
  <brief_title>Remimazolam and Remifentanil Without Neuromuscular Blocking Agent</brief_title>
  <official_title>General Anesthesia Using Remimazolam and Remifentanil Without Neuromuscular Blocking Agent: Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Remimazolam is a novel drug approved for induction and maintenance of general anesthesia.&#xD;
      This study aims to check the appropriate dose and patient response by administering&#xD;
      remimazolam and remifentanil in surgery that does not require a neuromuscular blocking&#xD;
      agents.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">August 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 23, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Remimazolam induction dose</measure>
    <time_frame>During the anesthesia induction (from initiation of anesthesia until the insertion of laryngeal mask airway)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Remimazolam maintenance dose</measure>
    <time_frame>During the anesthesia maintenance (from the insertion of laryngeal mask airway until stopping remimazolam infusion)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use of rescue midazolam</measure>
    <time_frame>During the anesthesia (from initiation of anesthesia until stopping remimazolam infusion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue rocuronium</measure>
    <time_frame>During the anesthesia (from initiation of anesthesia until stopping remimazolam infusion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of flumazenil</measure>
    <time_frame>During the anesthesia recovery (from stopping remimazolam infusion until the recovery of consciousness)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Myoma;Uterus</condition>
  <condition>Polyp Endometrium</condition>
  <condition>Unspecified Condition Associated With Female Genital Organs and Menstrual Cycle</condition>
  <arm_group>
    <arm_group_label>General anesthesia using remimazolam and remifentanil</arm_group_label>
    <description>Adult female patients scheduled for gynecological surgery under general anesthesia using remimazolam and remifentanil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam</intervention_name>
    <description>Loading for anesthesia induction: Remimazolam 12 mg/kg/h until loss of consciousness Continuous infusion for anesthesia maintenance: Remimazolam 1-2 mg/kg/h under the Bispectral index monitoring</description>
    <arm_group_label>General anesthesia using remimazolam and remifentanil</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult woman scheduled for gynecological surgery under general anesthesia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult woman scheduled for gynecological surgery under general anesthesia&#xD;
&#xD;
          -  American Society of Anesthesiology grade 1 or 2&#xD;
&#xD;
          -  When using a laryngeal mask airway to maintain general anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Underlying diseases: liver, kidney, brain nervous system, glaucoma&#xD;
&#xD;
          -  Patients with BMI greater than 30 and less than 18.5&#xD;
&#xD;
          -  Patients diagnosed with sleep apnea&#xD;
&#xD;
          -  Alcohol or drug dependent patients&#xD;
&#xD;
          -  Patients with severe or acute respiratory failure&#xD;
&#xD;
          -  Lactose intolerance&#xD;
&#xD;
          -  Dextran 40 hypersensitivity&#xD;
&#xD;
          -  Patients in shock or coma&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hyo-Seok Na</last_name>
    <phone>82317877507</phone>
    <email>hsknana@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Hyo-Seok Na</last_name>
      <phone>81317877507</phone>
      <email>hsknana@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Hyo-Seok Na</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

